Swedbank
NRIX icon

Swedbank’s Nurix Therapeutics NRIX Stock Holding History

Swedbank’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.66M Buy
70,000
+5,000
+8% +$125K ﹤0.01% 644
2026
Q2 		$1.58M Buy
+65,000
New +$1.11M ﹤0.01% 661

Other funds holding NRIX

Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return
WestHill Financial Advisors
WestHill Financial Advisors San Rafael, California $597M AUM 13.09% 1-Year Est. Return
Profund Advisors
Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return
China Universal Asset Management Company
China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return
RAM Investment Partners
RAM Investment Partners Bellevue, Washington $631M AUM 11.73% 1-Year Est. Return
ProShare Advisors
ProShare Advisors Bethesda, Maryland $69.5B AUM 31.38% 1-Year Est. Return
PR
PSP Research Newtown Square, Pennsylvania $146M AUM 39.94% 1-Year Est. Return
Concurrent Investment Advisors
Concurrent Investment Advisors Tampa, Florida $14.5B AUM 24.52% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $57B AUM 43.56% 1-Year Est. Return

Swedbank's NRIX Position: Q3 2026 in Review

Swedbank increased its Nurix Therapeutics (NRIX) stake by 7.7% in Q3 2026, buying an estimated $125K and bringing the position to 70,000 shares worth $1.66M. The position accounts for ﹤0.01% of the portfolio, ranked #644.

Swedbank first reported a position in NRIX in Q2 2026 and has held it in 2 quarters since. 37 funds tracked by Wall St. Rank hold NRIX as of Q3 2026.

  • Swedbank held 70,000 shares of Nurix Therapeutics worth $1.66M as of Q3 2026.
  • Swedbank bought 5,000 Nurix Therapeutics shares in Q3 2026, an estimated $125K.
  • Nurix Therapeutics made up ﹤0.01% of Swedbank's portfolio in Q3 2026, its #644 holding.
  • Swedbank first reported a position in Nurix Therapeutics in Q2 2026 and has held it in 2 quarters since.
  • 37 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q3 2026.

Based on Swedbank's 13F filing for Q3 2026, filed 27 Oct 2026.